We are live on
!
Find out more
ACM
Argyle Capital Management Portfolio holdings
AUM
$347M
1-Year Est. Return
44.33%
This Fund
S&P 500
This Quarter
Est. Return
+0.84%
1 Year Est. Return
+44.33%
3 Year Est. Return
+95.77%
5 Year Est. Return
+124.66%
10 Year Est. Return
+325.03%
AUM
$174M
AUM Growth
–
Cap. Flow
+$176M
Cap. Flow
% of AUM
100.96%
Top 10 Holdings %
Top 10 Hldgs %
24.86%
Holding
108
New
108
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$4.91M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$4.88M |
| 3 |
Merck
MRK
|
+$4.75M |
| 4 |
Verizon
VZ
|
+$4.67M |
| 5 |
AT&T
T
|
+$4.31M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.77% |
| 2 | Technology | 14.15% |
| 3 | Industrials | 11.26% |
| 4 | Energy | 10.86% |
| 5 | Consumer Staples | 8.75% |
Similar funds
GCP
AWA
WC
LAM
FFA
VW
1CP
NC
Argyle Capital Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Argyle Capital Management, which disclosed 108 positions worth $174M. Its ten largest holdings account for 25% of the portfolio.
Its largest position is Pfizer: 177,740 shares worth $4.72M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, followed by Technology and Industrials.
- Argyle Capital Management's largest Q2 2013 buy was Pfizer: 177,740 shares worth $4.72M.
- Argyle Capital Management's ten largest holdings make up 25% of its $174M portfolio in Q2 2013.
- Argyle Capital Management disclosed 108 positions in Q2 2013, its first 13F filing on record.
Based on Argyle Capital Management's 13F filing for Q2 2013, filed 31 Jul 2013.